top of page

Nelson Advisors: Europe's Next Three Big HealthTech, Health AI and MedTech Opportunities. Where Founders and Investors Should Spend the Next 12 Months

Writer: Nelson Advisors
Nelson Advisors
7 minutes ago
12 min read
Nelson Advisors: Europe's Next Three Big HealthTech, Health AI and MedTech Opportunities. Where Founders and Investors Should Spend the Next 12 Months
Nelson Advisors: Europe's Next Three Big HealthTech, Health AI and MedTech Opportunities. Where Founders and Investors Should Spend the Next 12 Months

European healthtech is short of capital and long on deadlines, and that combination is where the next returns will come from. The three biggest opportunities for the next 12 months are clinical AI that goes beyond the scribe, the data plumbing the European Health Data Space now makes compulsory, and a medtech market that Brussels is finally trying to reopen.


Why the next 12 months are different


Start with the money. Tech.eu's funding tracker counts €7.7B raised by European healthtech companies in 2025 across 439 rounds. The first quarter of 2026 came in at €1.6B, down 36.9% on a year earlier. The headline recovered later, but a single round did much of the work: Isomorphic Labs' $2.1B Series B in May. Strip out the mega-rounds and the picture is fewer deals, bigger cheques, and generalist capital drifting to AI, robotics and defence.


That is uncomfortable if you are raising. It is useful if you are choosing where to build, because scarce capital coincides with three regulatory clocks that create buyers with deadlines.


  • 26th March 2027. The first operative provisions of the European Health Data Space start to apply, and member states must have their health data access bodies in place.

  • 2nd August 2028. High-risk obligations under the EU AI Act now bite for AI inside medical devices, a year later than first legislated.

  • Live negotiation. The Commission's December 2025 proposal to simplify the Medical Devices Regulation and its diagnostics twin is working through Parliament and Council.


Each clock changes who has to buy, by when, and what counts as a moat. The rest of this post is about reading those clocks correctly. One caveat before we start: this is a market view, not investment advice, and several of the rules below are still moving.


Opportunity 1: Clinical AI after the scribe


The ambient scribe has won the argument and is losing its margin. The opportunity now sits one layer up: software that takes the transcript and does the work that follows it.


England shows how quickly this happened. NHS England's guidance on ambient scribing products reached its third version in July 2026, and a national supplier registry opened early in the year to tidy up what one law firm called a "Wild West" market. Two hospital groups, Leicester and Northamptonshire, are deploying Accurx Scribe across their organisations, on a contract reported at £1.9m. The same report has a regional commissioner in Hampshire paying £87,500 for an unlimited-user licence.


Read those prices carefully. Scribing is being bought by the region, not by the clinician, and at numbers that will not support a dozen venture-backed vendors. A real-time evaluation in the English Midlands reached the same verdict from the buyer's side: the market is still immature and volatile, which leaves health systems unsure whom to back.


So the transcript is becoming a commodity input. Value moves to three places.


Work that follows the note. Clinical coding, referral letters, discharge summaries, order entry, registry submissions and insurer correspondence all start from the same conversation. In activity-funded systems such as Germany and France, coding accuracy is hospital income. That moves the buyer from the clinical informatics lead to the finance director, who has a larger budget and a simpler question.


Everyone who is not a doctor. Nurses, community teams, mental health services and social workers document more and have had less software built for them. The Hampshire purchase was a tool that began in social care. Europe's workforce gap is widest here: a Commission official recently put the current shortfall at roughly 1.2 million health workers, with a path to 4 million if nothing changes.


Local depth. American scribe vendors are strong in English and in US record systems. They are weak in German discharge conventions, French coding rules, Polish, Italian and the Nordic languages, and in the regional record systems that dominate each country. The Accurx deal is instructive: the product is powered by Sweden's Tandem Health. Incumbents with distribution need engines, and engines need distribution. Partnership is a legitimate route to market, not a consolation prize.


The regulatory window


The EU's Digital Omnibus has pushed the AI Act's high-risk obligations out to 2 December 2027 for standalone systems and 2 August 2028 for AI inside regulated products, medical devices included. Industry wanted more. MedTech Europe lobbied for a single pathway through the device rules and did not get it: industrial AI won a carve-out, medical technology stayed in scope.


The practical reading is a two-year window, not a holiday. Hospital procurement teams will start asking for AI Act readiness well before August 2028. A company that has a device-grade quality system and published outcome data by late 2027 will be selling into tenders its competitors cannot enter.


Where to spend time


  • Founders: pick one workflow where saved minutes turn into money, such as coding uplift, extra clinic slots or fewer agency shifts. Sell to regions and hospital groups, and publish the numbers.


  • Investors: be sceptical of scribe-only companies on per-seat pricing. Ask what happens to revenue when a national framework sets the price, and what the product does after the note is written.


Opportunity 2: The data plumbing EHDS makes compulsory


The European Health Data Space is the largest forced IT upgrade European healthcare has faced, and most of the spending has not started. That makes it the least glamorous and most dependable opportunity on this list.


The dates matter, because they are often misquoted. The regulation entered into force on 26 March 2025. General application begins on 26 March 2027, which is also the Commission's deadline for the key implementing acts that turn principles into technical specifications. The heavier obligations arrive in March 2029: exchange of the first priority data categories, and most of the rules on secondary use. A second wave follows in 2031.


So the next 12 months are the specification year. Whoever is in the room, and in the pilots, while the specifications settle will be the default supplier when the buying starts. Three sub-markets follow.


Conformity tooling for record-system vendors


EHDS creates a single-market regime for electronic health record systems. Vendors must build two harmonised components, one for interoperability and one for access logging, then declare conformity, apply a CE mark and register the product in an EU database.


Europe has hundreds of small, regional record-system vendors: GP systems, specialty clinic software, laboratory and radiology systems. Few have a regulatory team. They need adapters to the European exchange format, test harnesses and documentation they can buy, not build. Their customers face a legal deadline, which is the best sales condition there is.


Readiness for data holders


Hospitals, laboratories, registries, and many medtech and digital health companies become "health data holders". They will have to describe their datasets and make them available, on request, through national health data access bodies that member states are due to have in place by March 2027. Analysis happens inside secure environments, and personal data does not leave.

That creates demand for catalogues, de-identification, data-quality tooling, conversion to common research models and secure processing environments.


One Italian roadmap pencils in 2027 to 2029 for exactly this: standing up the national access body, converting healthcare databases and piloting data permits. Multiply that by 27 countries and several thousand institutions.

Founders outside classic health IT should note the scope. If your device or app generates health data in the EU, you are probably a data holder too. Compliance tooling for medtech companies is a niche almost nobody is serving.


Evidence businesses built on top


Once permits flow, the interesting companies appear: real-world evidence for reimbursement dossiers, trial feasibility and recruitment, post-market surveillance that device makers already owe under the device rules, and validation datasets for clinical AI. Finland legislated for secondary use first and has led the joint European projects that are writing the guidelines, so Nordic founders start with an advantage here.


The honest caveat


Cross-border secondary use at scale is a 2029 story at the earliest. A pure data-marketplace pitch today is early by years. The sequence that works is compliance revenue now, with the evidence business as an option that revenue pays for.


Where to spend time


  • Founders: join a national access-body pilot or a regional hospital consortium in 2027. Sell compliance as a service, priced per system or per dataset, to buyers with a deadline.


  • Investors: treat this as infrastructure with strategic exits. Record-system incumbents and data-platform groups will buy rather than build. Look for teams with standards expertise and one country fully solved, not a pan-European slide.


Opportunity 3: Medtech that replaces scarce labour and moves care out of hospital


Devices are where European healthtech money is quietly going, and the rules that made Europe a poor place to launch them are being rewritten. The opening is in hardware-plus-software products that do a job a health system can no longer staff.


Look at the larger rounds of 2026 below the mega-deal line. Tech.eu's first-half list includes DentalMonitoring at €71M, Neurent Medical at €63M, Vitestro at €60M and Uromems at €52M. Vitestro builds a robot that draws blood. None of these is a chatbot. In the third quarter, the most active healthtech investor in Europe was the European Investment Bank, a sign that public and quasi-public capital is filling the gap generalist venture left.


The rules are moving, slowly


On 16 December 2025 the Commission proposed a targeted overhaul of the device and diagnostics regulations. The headline ideas are a move away from fixed five-year certificates towards lifecycle oversight, lighter clinical evaluation for well-established technologies, and dedicated routes for breakthrough and orphan devices.


It is not law yet. Parliament tabled nearly 800 amendments in July. The health committee vote is pencilled in for 3 December, with a plenary position early in 2027 and the Council aiming for its own position by the end of this year. Realistically the new text applies in 2027 at the earliest.


The right posture is to plan certification under today's rules and treat reform as upside. Investors who priced European device companies off the delays of 2021 to 2024 should revisit the discount.


Nelson Advisors: Europe's Next Three Big HealthTech, Health AI and MedTech Opportunities. Where Founders and Investors Should Spend the Next 12 Months
Nelson Advisors: Europe's Next Three Big HealthTech, Health AI and MedTech Opportunities. Where Founders and Investors Should Spend the Next 12 Months

Sub-markets worth the time


Automation of routine procedures. Blood draws, ultrasound acquisition, pharmacy compounding, sterile processing and laboratory handling are high-volume, protocol-driven and short of staff. The buyer case is simple arithmetic on shifts. These products are capital-intensive, which is why few are funded and why those that reach the market face little competition.


Hospital-level care at home. Region Stockholm picked a consortium including Philips for a large hospital-at-home programme in May. France already pays for remote monitoring through its mainstream tariff route, and is the reimbursement leader in Europe on that measure. Hospital-at-home needs kit that most monitoring start-ups do not make: continuous sensing, home infusion, logistics and a command centre. The gap is in the components and the orchestration software, not another dashboard.


Orphan and paediatric devices. Small volumes and high certification costs pushed manufacturers to withdraw niche products. The reform targets this directly, and MedTech Europe wants paediatric devices explicitly covered. A priority route, a small field and hospital buyers with no alternative make for a durable business, if not a venture-scale one on its own. It works best as a second product line for a company that already holds a quality system.


Mind the country gap


Adoption is uneven in ways that should drive launch order. ING's research found that 22 to 27% of consultations are remote in Portugal, the Netherlands, Denmark, Sweden and Spain. The figures for Germany and France are 4% and 1%. Founders default to Germany, France and the UK because they are large. For home-based care, the Nordics, Iberia and the Netherlands are the faster first markets.


Where to spend time


  • Founders: design the product around a tariff or a staffing line that exists today. Run the first deployment where care already happens outside hospital.


  • Investors: pair equity with venture debt and public co-funding. Underwrite reform as an option, not a base case.


The under-commercialised corners


Six sub-markets have real demand, a visible payer and very little organised competition. They sit inside or beside the three themes above.


Sub-market

Why it is under-served

A credible wedge

Menopause and midlife women's health

Women's health took about 6% of private healthcare funding worldwide from 2020 to 2025. Europe has one unicorn in the category.

Employer and insurer-paid clinics with software, not another tracking app

Endometriosis and gynaecological diagnostics

Diagnosis is slow and invasive, and investors have treated it as niche

Non-invasive tests and AI-read imaging sold to gynaecology networks

Long-term and social care

Fragmented operators, municipal buyers and thin margins keep venture away

Documentation AI, falls sensing and medication management sold to care-home chains

Orphan and paediatric devices

Certification cost outweighs volume under current rules

A second product line on an existing quality system, using the new priority routes

Southern and Central-Eastern Europe as first markets

Founders default to Germany, France and the UK

Launch where remote care is already routine and vendor competition is thin

Dental, hearing and eye care

Seen as consumer retail, not healthtech

AI monitoring and diagnostics sold to consolidated clinic chains, paid out of pocket


Two of these deserve a longer look.


Women's health is the clearest mispricing. The same analysis found that 44% of Europe's 540 femtech start-ups have raised no external money. Dealroom's data shows femtech's share of health venture funding falling from 2.2% in 2016 to 0.6% in 2026. Meanwhile menopause is the fastest-growing funding category within European women's health, and the UK refreshed its Women's Health Strategy in April. Capital is leaving a category as policy and demand arrive. The winners will look like care providers with strong software, funded partly by non-dilutive and revenue-based money.


Long-term care is the largest market nobody pitches. The workforce gap is worse here than in hospitals, and the buyers are care-home groups and municipalities that few venture investors have ever met. Eastern and southern countries are also losing staff to the north and west, so the need for labour-saving tools is sharpest where vendors are fewest.


One market that is not undiscovered


Prescription apps are a cautionary tale. Germany's scheme produced 423,000 prescriptions in 2024 and a market of about €152M. Yet as of late September 2026 the insurer AOK counted 50 permanently listed apps and 13 still on trial, and roughly a fifth of all entrants have been delisted. France's equivalent fast track had produced 13 evaluations and four favourable opinions by this autumn.

The pathways are real, but they pay for evidence, not for apps. A stand-alone digital therapeutic remains a hard business. The same software bundled with a device, a clinic or a service line has a far better chance.


A 12-month playbook


The next year rewards people who work to the regulatory calendar. Four dates anchor it: the Parliament committee vote on device reform on 3 December 2026, the EHDS milestone on 26 March 2027, Parliament's plenary position on devices in early 2027, and the first AI Act high-risk deadline on 2 December 2027.


For founders


  1. Sell to the budget, not the enthusiast. Find the line item your product reduces: agency staffing, coding leakage, bed days, compliance cost. If you cannot name it, the pilot will not convert.


  2. Choose the first country on adoption, not size. Nordics, the Netherlands and Iberia for home-based care. England for clinical AI at scale. Germany and France when you have evidence and patience.


  3. Build the quality system early. Device-grade processes and AI Act documentation are a cost in 2027 and a moat in 2028.


  4. Get into an EHDS pilot. National access bodies and hospital consortia are choosing partners now, while specifications are still being written.


  5. Partner for distribution. Incumbent record-system and device companies need new products and own the channel. A white-label deal can be worth more than a sales team.


  6. Stack non-dilutive money. EIB venture debt, European Innovation Council funding and national grants are doing work that Series A funds did in 2021.


For investors


  1. Spend time with buyers. A day with a hospital finance director, a regional procurement lead or a care-home operator will tell you more than ten pitch meetings.


  2. Reprice regulation. Device reform and the AI Act delay both lower near-term risk. Compliance capability is now a diligence item and a source of advantage, not just a cost.


  3. Back the layer above the commodity. In clinical AI, that means workflow and revenue-cycle products with measured outcomes. In data, it means compliance revenue with an evidence option.


  4. Look where others are leaving. Women's health and long-term care have demand, policy support and falling competition for deals.


  5. Plan the exit in Europe. Consolidation is the likelier path than a listing. One analysis put European healthtech M&A at €31.8B, with AI-driven platforms fetching premium multiples. Know the three likely acquirers before you invest.


The takeaway


Europe's healthtech opportunity in 2027 is not a new technology. It is three sets of buyers who have run out of alternatives: hospitals that cannot hire, institutions that must comply, and health systems that have to move care out of buildings they cannot afford to expand.


The companies that win will be unglamorous by the standards of the last cycle. They will sell coding, conformity and blood draws. They will launch in Stockholm, Lisbon or Leicester before Berlin. They will treat regulation as a product feature.


Three things would change this view. If device reform stalls in trilogue, the medtech thesis slips a year. If member states miss their EHDS milestones, compliance spending moves right with them. And if national frameworks commoditise clinical AI faster than vendors can climb the workflow stack, the first opportunity narrows to a handful of winners. Each is worth watching, and none removes the underlying shortage of people, money and time that is driving all three.


Nelson Advisors > European Healthcare Technology Investment Banking


Nelson Advisors specialise in Mergers and Acquisitions for European HealthTech, MedTech, Digital Health, Healthcare IT, Healthcare AI companies in the Lower to Mid Market ranging from $25M to $250M EV. www.nelsonadvisors.co.uk


Healthcare.Digital is the Google News approved HealthTech and MedTech Thought Leadership platform for Nelson Advisors, positioning them as a specialised authority on European Healthcare Technology M&A and strategic corporate development. https://www.healthcare.digital 


Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb 



Nelson Advisors LLP


Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT




Meet Nelson Advisors @ Events in 2026


Digital Health Rewired > March 2026 > Birmingham, UK  


NHS ConfedExpo  > June 2026 > Manchester, UK 


HLTH Europe > June 2026, Amsterdam, Netherlands


HIMSS AI in Healthcare > July 2026, New York, USA


Bits & Pretzels > September 2026, Munich, Germany  


HealthInvestor Healthcare Summit > September 2026, London, UK 


World Health Summit 2026 > October 2026, Berlin, Germany


HLTH USA 2026 > October 2026, USA


Global Health Exhibition 2026 > October 2026, Riyadh, Saudi Arabia


Web Summit 2026 > November 2026, Lisbon, Portugal  


MEDICA 2026 > November 2026, Düsseldorf, Germany


Leaders in Health Summit 2026 > November 2026, London, UK 


Venture Capital World Summit > December 2026, Toronto, Canada


Meet Nelson Advisors @ Events in 2027


Digital Health Rewired > March 2027 > Birmingham, UK


Barclays Health Elevate > March 2027, London, UK 


NHS ConfedExpo  > June 2027 > Manchester, UK 


HLTH Europe > June 2027, Amsterdam, Netherlands


Nelson Advisors specialise in Mergers and Acquisitions for European HealthTech, MedTech, Digital Health, Healthcare IT, Healthcare AI companies in the Lower to Mid Market ranging from $25M to $250M EV. www.nelsonadvisors.co.uk
Nelson Advisors specialise in Mergers and Acquisitions for European HealthTech, MedTech, Digital Health, Healthcare IT, Healthcare AI companies in the Lower to Mid Market ranging from $25M to $250M EV. www.nelsonadvisors.co.uk

Comments


Commenting on this post isn't available anymore. Contact the site owner for more info.
bottom of page